|
시장보고서
상품코드
1787002
맞춤형 의료 시장 : 규모, 점유율, 동향, 산업 분석 보고서 - 제품별, 최종 용도별, 지역별 시장 예측(2025-2034년)Personalized Medicine Market Size, Share, Trend, Industry Analysis Report By Product (Personalized Medicine Diagnostics, Personalized Medicine Therapeutics, Others), By End Use, By Region - Market Forecast, 2025-2034 |
||||||
Polaris Market Research의 최근 조사에 따르면 맞춤형 의료 시장 규모는 2034년까지 1조 3,002억 달러에 이를 것으로 예측됩니다. 이 보고서는 현재 시장 역학을 상세하게 파악하고 미래 시장 성장에 대한 분석을 제공합니다.
맞춤형 의료 시장은 유전자, 환경 및 라이프스타일 데이터를 임상 결정의 지침으로 활용하고 각 환자의 특성에 맞는 치료를 수행하는 데 중점을 둡니다. 유전체 해독, 분자진단, 바이오인포매틱스의 급속한 진보는 예측, 예방, 정확한 표적 개입을 가능하게 하고, 전통적인 헬스케어를 일변시켰습니다. 바이오마커를 이용한 치료법의 임상적 통합은 종양학, 신경학 및 순환기학에 걸친 치료 프로토콜을 재구성합니다. 가치관에 의한 의료가 중시되게 됨으로써, 부작용을 최소한으로 억제해, 치료 성적을 향상시키는 표적 치료에 대한 수요가 가속하고 있습니다. 직접 소비자에게 제공되는 유전자 검사 증가 및 환자 의식 증가로 맞춤형 웰빙과 예방 전략에 대한 접근이 확대되고 있습니다.
제약 회사는 임상 검사 결과 및 규제 당국의 승인 효율성을 최적화하기 위해 바이오 마커 탐색 및 동반자 진단에 투자합니다. 시장 동향에는 멀티오믹스 프로파일링, AI를 활용한 의사결정 도구, 개인화된 디지털 치료로의 전환이 포함됩니다. 개인화된 케어 모델을 1차 케어의 틀에 통합하고, 전자 의료 기록을 활용하여 임상-유전체 데이터의 통합을 지원하는 비즈니스 기회가 있습니다. 정밀의료 치료의 보험 적용에 대한 지불자의 관심 증가는 새로운 상업적 경로를 창출하고 있습니다.
희귀질환 유전체학 및 계층화 의료 이니셔티브에 중점을 둔 관민 파트너십은 혁신 파이프라인을 강화하고 있습니다. 진단학, 치료학, 데이터 사이언스의 융합은 맞춤형 의료의 잠재력을 극대화하고 현대 의료의 핵심 기둥이 되었습니다. 맞춤 영양학 및 미생물학에 중점을 둔 개입이 받아들여지고 있는 것도 전인적인 헬스케어로의 폭넓은 시프트를 시사하고 있습니다. 맞춤형 의료 시장은 이해관계자가 임상적 유용성, 기술적 능력, 규제 당국의 지원을 조정하고 맞춤형 헬스케어 솔루션을 추진함으로써 향후 수년간 급속히 진화할 것으로 예측됩니다.
맞춤형 의료 시장 보고서 하이라이트
제품별로는 개별화 영양 및 건강 부문이 2024년 매출 점유율에서 -33%를 차지했습니다. 예방 의료 및 생활 습관병에 대한 소비자의 의식이 높아짐에 따라 맞춤형 영양 웰빙 솔루션에 대한 수요가 높아지고 있습니다.
최종 용도별로 병원 부문은 2024년 최대 점유율을 차지했습니다. 첨단 인프라 및 분자 검사 플랫폼에 대한 광범위한 접근으로 병원은 정밀의료를 수행하기 위한 중요한 기반이 되었습니다.
북미는 유전체 기술, 고도 진단, 정밀 치료가 임상 현장에서 많이 채용되고 있기 때문에 2024년 매출 점유율의 40%를 차지했습니다.
아시아태평양의 맞춤형 의료 시장은 2025-2034년 CAGR 12.2%로 성장할 것으로 예측되고 있습니다. 인구밀도가 높은 국가에서의 맞춤형 의료에 대한 수요의 급증, 의료 지출 증가, 유전체 서비스에 대한 액세스 확대가 시장 확대의 원동력이 되고 있기 때문입니다.
세계 주요 기업으로는 Abbott, ASURAGEN, INC., Biogen, Celera Diagnostics LLC., Dako A/S, Danaher Corporation(Cepheid, Inc.), Decode Genetics, Inc., Exact Sciences Corporation, Exagen Inc., GE Healthcare, Genelex, Illumina, Inc., Precision Biologics, QIAGEN 등이 있습니다.
목차
제1장 서론
제2장 주요 요약
제3장 조사 방법
제4장 세계의 맞춤형 의료 시장 인사이트
- 시장 현황
- 맞춤형 의료 시장 역학
- 성장 촉진요인 및 기회
- 만성질환 및 희소질환 유병률 증가
- 제약기업 및 생명공학 기업에 의한 연구개발 투자 증가
- 성장 억제요인 및 과제
- 높은 개발 및 진단 비용
- 성장 촉진요인 및 기회
- PESTEL 분석
- 맞춤형 의료 시장의 용도 동향
- 밸류체인 분석
제5장 세계의 맞춤형 의료 시장 : 제품별
- 주요 조사 결과
- 서문
- 맞춤형 의료 진단
- 맞춤형 의료 치료
- 맞춤형 의료
- 개별화 영양과 건강
제6장 세계의 맞춤형 의료 시장 : 최종 용도별
- 주요 조사 결과
- 서문
- 병원
- 진단센터
- 연구 및 학술기관
- 기타
제7장 세계의 맞춤형 의료 시장 : 지역별
- 주요 조사 결과
- 서문
- 맞춤형 의료 시장 평가 : 지역별(2020-2034년)
- 북미
- 북미 : 제품별(2020-2034년)
- 북미 : 최종 용도별(2020-2034년)
- 미국
- 캐나다
- 멕시코
- 유럽
- 유럽 : 제품별(2020-2034년)
- 유럽 : 최종 용도별(2020-2034년)
- 영국
- 프랑스
- 독일
- 이탈리아
- 스페인
- 네덜란드
- 러시아
- 기타 유럽
- 아시아태평양
- 아시아태평양 : 제품별(2020-2034년)
- 아시아태평양 : 최종 용도별(2020-2034년)
- 중국
- 인도
- 말레이시아
- 일본
- 인도네시아
- 한국
- 호주
- 기타 아시아태평양
- 중동 및 아프리카
- 중동 및 아프리카 : 제품별(2020-2034년)
- 중동 및 아프리카 : 최종 용도별(2020-2034년)
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 남아프리카
- 기타 중동 및 아프리카
- 라틴아메리카
- 라틴아메리카 : 제품별(2020-2034년)
- 라틴아메리카 : 최종 용도별(2020-2034년)
- 브라질
- 아르헨티나
- 기타 라틴아메리카
제8장 경쟁 구도
- 확대 및 인수 분석
- 확대
- 인수
- 제휴, 협업, 합의 및 공개
제9장 기업 프로파일
- Abbott
- ASURAGEN, INC.
- Biogen
- Celera Diagnostics LLC.
- Dako A/S
- Danaher Corporation(Cepheid, Inc.)
- Decode Genetics, Inc.
- Exact Sciences Corporation
- Exagen Inc.
- GE Healthcare
- Genelex
- Illumina, Inc.
- Precision Biologics
- QIAGEN
The personalized medicine market size is expected to reach USD 1,300.20 billion by 2034, according to a new study by Polaris Market Research. The report "Personalized Medicine Market Size, Share, Trend, Industry Analysis Report By Product (Personalized Medicine Diagnostics, Personalized Medicine Therapeutics, Others), By End Use, By Region - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The personalized medicine market focuses on tailoring medical treatment to the individual characteristics of each patient, using genetic, environmental, and lifestyle data to guide clinical decisions. Rapid advances in genomic sequencing, molecular diagnostics, and bioinformatics have transformed traditional healthcare by enabling predictive, preventive, and precisely targeted interventions. The integration of biomarker-based therapies into clinical practice is reshaping treatment protocols across oncology, neurology, and cardiology. Increasing emphasis on value-based care is accelerating demand for targeted drugs that minimize adverse effects and improve therapeutic outcomes. The growth in direct-to-consumer genetic testing and increasing patient awareness is expanding access to customized wellness and preventive strategies.
Pharmaceutical companies are investing in biomarker discovery and companion diagnostics to optimize clinical trial outcomes and regulatory approval efficiency. Market trends include a shift toward multi-omics profiling, AI-powered decision-making tools, and personalized digital therapeutics. Opportunities lie in integrating personalized care models into primary care frameworks and leveraging electronic health records to support clinical-genomic data convergence. Increasing interest from payers in covering precision medicine therapies is creating new commercial pathways.
Public-private partnerships focused on rare disease genomics and stratified medicine initiatives are enhancing innovation pipelines. The convergence of diagnostics, therapeutics, and data science is unlocking the full potential of personalized care, making it a central pillar of modern medicine. Growing acceptance of personalized nutrition and microbiome-focused interventions also signals a broader shift toward holistic health management. The personalized medicine market is expected to evolve rapidly in the coming years as stakeholders align clinical utility, technological capabilities, and regulatory support to advance individualized healthcare solutions.
Personalized Medicine Market Report Highlights
By product, the personalized nutrition & wellness segment accounted for ~33% of the revenue share in 2024. Growing consumer awareness about preventive healthcare and lifestyle-related diseases has increased the demand for tailored nutrition and wellness solutions.
Based on end use, the hospitals segment accounted for the largest share in 2024. Advanced infrastructure and broader access to molecular testing platforms make hospitals key centers for implementing precision medicine.
North America accounted for ~40% of the revenue share in 2024 due to high adoption of genomic technologies, advanced diagnostics, and precision therapeutics across clinical settings.
The personalized medicine market in Asia Pacific is expected to register a CAGR of 12.2% from 2025 to 2034, as surging demand for tailored healthcare in densely populated countries, rising healthcare spending, and growing access to genomic services are driving expansion.
A few global key players include Abbott; ASURAGEN, INC.; Biogen; Celera Diagnostics LLC.; Dako A/S; Danaher Corporation (Cepheid, Inc.); Decode Genetics, Inc.; Exact Sciences Corporation; Exagen Inc.; GE Healthcare; Genelex; Illumina, Inc.; Precision Biologics; and QIAGEN.
Polaris Market Research has segmented the personalized medicine market report on the basis of product, end use, and region:
By Product Outlook (Revenue, USD Billion, 2020-2034)
Personalized Medicine Diagnostics
Genetic Testing
Direct-To-Consumer (DTC) Diagnostics
Others
Personalized Medicine Therapeutics
Pharmaceutical
Genomic Medicine
Medical Devices
Personalized Medical Care
Personalized Nutrition & Wellness
By End Use Outlook (Revenue, USD Billion, 2020-2034)
Hospitals
Diagnostic Centers
Research & Academic Institutes
Others
By Regional Outlook (Revenue, USD Billion, 2020-2034)
North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Vietnam
Australia
Rest of Asia Pacific
Latin America
Argentina
Brazil
Mexico
Rest of Latin America
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Rest of Middle East & Africa
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Personalized Medicine Market Insights
- 4.1. Personalized Medicine Market - Market Snapshot
- 4.2. Personalized Medicine Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Increasing Prevalence of Chronic and Rare Diseases
- 4.2.1.2. Increased Investment in R&D by Pharma and Biotech Firms
- 4.2.2. Restraints and Challenges
- 4.2.2.1. High development and diagnostic costs
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Personalized Medicine Market Application Trends
- 4.6. Value Chain Analysis
5. Global Personalized Medicine Market, by Product
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
- 5.3. Personalized Medicine Diagnostics
- 5.3.1. Global Personalized Medicine Market, by Personalized Medicine Diagnostics, by Region, 2020-2034 (USD Billion)
- 5.3.2. Genetic Testing
- 5.3.2.1. Global Personalized Medicine Market, by Genetic Testing, by Region, 2020-2034 (USD Billion)
- 5.3.3. Direct-To-Consumer (DTC) Diagnostics
- 5.3.3.1. Global Personalized Medicine Market, by Direct-To-Consumer (DTC) Diagnostics, by Region, 2020-2034 (USD Billion)
- 5.3.4. Others
- 5.3.4.1. Global Personalized Medicine Market, by Others, by Region, 2020-2034 (USD Billion)
- 5.4. Personalized Medicine Therapeutics
- 5.4.1. Global Personalized Medicine Market, by Personalized Medicine Therapeutics, by Region, 2020-2034 (USD Billion)
- 5.4.2. Pharmaceutical
- 5.4.2.1. Global Personalized Medicine Market, by Pharmaceutical, by Region, 2020-2034 (USD Billion)
- 5.4.3. Genomic Medicine
- 5.4.3.1. Global Personalized Medicine Market, by Genomic Medicine, by Region, 2020-2034 (USD Billion)
- 5.4.4. Medical Devices
- 5.4.4.1. Global Personalized Medicine Market, by Medical Devices, by Region, 2020-2034 (USD Billion)
- 5.5. Personalized Medical Care
- 5.5.1. Global Personalized Medicine Market, by Personalized Medical Care, by Region, 2020-2034 (USD Billion)
- 5.6. Personalized Nutrition & Wellness
- 5.6.1. Global Personalized Medicine Market, by Others, by Personalized Nutrition & Wellness, 2020-2034 (USD Billion)
6. Global Personalized Medicine Market, by End Use
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
- 6.3. Hospitals
- 6.3.1. Global Personalized Medicine Market, by Hospitals, by Region, 2020-2034 (USD Billion)
- 6.4. Diagnostic Centers
- 6.4.1. Global Personalized Medicine Market, by Diagnostic Centers, by Region, 2020-2034 (USD Billion)
- 6.5. Research & Academic Institutes
- 6.5.1. Global Personalized Medicine Market, by Research & Academic Institutes, by Region, 2020-2034 (USD Billion)
- 6.6. Others
- 6.6.1. Global Personalized Medicine Market, by Othersr, by Region, 2020-2034 (USD Billion)
7. Global Personalized Medicine Market, by Geography
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Personalized Medicine Market Assessment, By Geography, 2020-2034 (USD Billion)
- 7.3. Personalized Medicine Market - North America
- 7.3.1. North America: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
- 7.3.2. North America: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
- 7.3.3. Personalized Medicine Market - U.S.
- 7.3.3.1. U.S.: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
- 7.3.3.2. U.S.: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
- 7.3.4. Personalized Medicine Market - Canada
- 7.3.4.1. Canada: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
- 7.3.4.2. Canada: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
- 7.3.5. Personalized Medicine Market - Mexico
- 7.3.5.1. Mexico: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
- 7.3.5.2. Mexico: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
- 7.4. Personalized Medicine Market - Europe
- 7.4.1. Europe: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
- 7.4.2. Europe: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
- 7.4.3. Personalized Medicine Market - UK
- 7.4.3.1. UK: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
- 7.4.3.2. UK: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
- 7.4.4. Personalized Medicine Market - France
- 7.4.4.1. France: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
- 7.4.4.2. France: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
- 7.4.5. Personalized Medicine Market - Germany
- 7.4.5.1. Germany: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
- 7.4.5.2. Germany: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
- 7.4.6. Personalized Medicine Market - Italy
- 7.4.6.1. Italy: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
- 7.4.6.2. Italy: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
- 7.4.7. Personalized Medicine Market - Spain
- 7.4.7.1. Spain: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
- 7.4.7.2. Spain: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
- 7.4.8. Personalized Medicine Market - Netherlands
- 7.4.8.1. Netherlands: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
- 7.4.8.2. Netherlands: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
- 7.4.9. Personalized Medicine Market - Russia
- 7.4.9.1. Russia: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
- 7.4.9.2. Russia: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
- 7.4.10. Personalized Medicine Market - Rest of Europe
- 7.4.10.1. Rest of Europe: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
- 7.4.10.2. Rest of Europe: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
- 7.5. Personalized Medicine Market - Asia Pacific
- 7.5.1. Asia Pacific: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
- 7.5.2. Asia Pacific: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
- 7.5.3. Personalized Medicine Market - China
- 7.5.3.1. China: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
- 7.5.3.2. China: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
- 7.5.4. Personalized Medicine Market - India
- 7.5.4.1. India: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
- 7.5.4.2. India: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
- 7.5.5. Personalized Medicine Market - Malaysia
- 7.5.5.1. Malaysia: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
- 7.5.5.2. Malaysia: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
- 7.5.6. Personalized Medicine Market - Japan
- 7.5.6.1. Japan: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
- 7.5.6.2. Japan: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
- 7.5.7. Personalized Medicine Market - Indonesia
- 7.5.7.1. Indonesia: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
- 7.5.7.2. Indonesia: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
- 7.5.8. Personalized Medicine Market - South Korea
- 7.5.8.1. South Korea: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
- 7.5.8.2. South Korea: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
- 7.5.9. Personalized Medicine Market - Australia
- 7.5.9.1. Australia: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
- 7.5.9.2. Australia: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
- 7.5.10. Personalized Medicine Market - Rest of Asia Pacific
- 7.5.10.1. Rest of Asia Pacific: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
- 7.5.10.2. Rest of Asia Pacific: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
- 7.6. Personalized Medicine Market - Middle East & Africa
- 7.6.1. Middle East & Africa: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
- 7.6.2. Middle East & Africa: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
- 7.6.3. Personalized Medicine Market - Saudi Arabia
- 7.6.3.1. Saudi Arabia: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
- 7.6.3.2. Saudi Arabia: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
- 7.6.4. Personalized Medicine Market - UAE
- 7.6.4.1. UAE: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
- 7.6.4.2. UAE: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
- 7.6.5. Personalized Medicine Market - Israel
- 7.6.5.1. Israel: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
- 7.6.5.2. Israel: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
- 7.6.6. Personalized Medicine Market - South Africa
- 7.6.6.1. South Africa: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
- 7.6.6.2. South Africa: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
- 7.6.7. Personalized Medicine Market - Rest of Middle East & Africa
- 7.6.7.1. Rest of Middle East & Africa: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
- 7.6.7.2. Rest of Middle East & Africa: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
- 7.7. Personalized Medicine Market - Latin America
- 7.7.1. Latin America: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
- 7.7.2. Latin America: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
- 7.7.3. Personalized Medicine Market - Brazil
- 7.7.3.1. Brazil: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
- 7.7.3.2. Brazil: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
- 7.7.4. Personalized Medicine Market - Argentina
- 7.7.4.1. Argentina: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
- 7.7.4.2. Argentina: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
- 7.7.5. Personalized Medicine Market - Rest of Latin America
- 7.7.5.1. Rest of Latin America: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
- 7.7.5.2. Rest of Latin America: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
8. Competitive Landscape
- 8.1. Expansion and Acquisition Analysis
- 8.1.1. Expansion
- 8.1.2. Acquisitions
- 8.2. Partnerships/Collaborations/Agreements/Exhibitions
9. Company Profiles
- 9.1. Abbott
- 9.1.1. Company Overview
- 9.1.2. Financial Performance
- 9.1.3. Product Benchmarking
- 9.1.4. Recent Development
- 9.2. ASURAGEN, INC.
- 9.2.1. Company Overview
- 9.2.2. Financial Performance
- 9.2.3. Product Benchmarking
- 9.2.4. Recent Development
- 9.3. Biogen
- 9.3.1. Company Overview
- 9.3.2. Financial Performance
- 9.3.3. Product Benchmarking
- 9.3.4. Recent Development
- 9.4. Celera Diagnostics LLC.
- 9.4.1. Company Overview
- 9.4.2. Financial Performance
- 9.4.3. Product Benchmarking
- 9.4.4. Recent Development
- 9.5. Dako A/S
- 9.5.1. Company Overview
- 9.5.2. Financial Performance
- 9.5.3. Product Benchmarking
- 9.5.4. Recent Development
- 9.6. Danaher Corporation (Cepheid, Inc.)
- 9.6.1. Company Overview
- 9.6.2. Financial Performance
- 9.6.3. Product Benchmarking
- 9.6.4. Recent Development
- 9.7. Decode Genetics, Inc.
- 9.7.1. Company Overview
- 9.7.2. Financial Performance
- 9.7.3. Product Benchmarking
- 9.7.4. Recent Development
- 9.8. Exact Sciences Corporation
- 9.8.1. Company Overview
- 9.8.2. Financial Performance
- 9.8.3. Product Benchmarking
- 9.8.4. Recent Development
- 9.9. Exagen Inc.
- 9.9.1. Company Overview
- 9.9.2. Financial Performance
- 9.9.3. Product Benchmarking
- 9.9.4. Recent Development
- 9.10. GE Healthcare
- 9.10.1. Company Overview
- 9.10.2. Financial Performance
- 9.10.3. Product Benchmarking
- 9.10.4. Recent Development
- 9.11. Genelex
- 9.11.1. Company Overview
- 9.11.2. Financial Performance
- 9.11.3. Product Benchmarking
- 9.11.4. Recent Development
- 9.12. Illumina, Inc.
- 9.12.1. Company Overview
- 9.12.2. Financial Performance
- 9.12.3. Product Benchmarking
- 9.12.4. Recent Development
- 9.13. Precision Biologics
- 9.13.1. Company Overview
- 9.13.2. Financial Performance
- 9.13.3. Product Benchmarking
- 9.13.4. Recent Development
- 9.14. QIAGEN
- 9.14.1. Company Overview
- 9.14.2. Financial Performance
- 9.14.3. Product Benchmarking
- 9.14.4. Recent Development
